<DOC>
	<DOCNO>NCT00435292</DOCNO>
	<brief_summary>Randomized , double-blind , placebo control parallel group , multi center study subject moderate-severe osteoarthritis .</brief_summary>
	<brief_title>Study Flavocoxid ( Limbrel ) v Naproxen Subjects With Mod-Severe Osteoarthritis Knee</brief_title>
	<detailed_description>This randomize , double blind , placebo control , parallel group , multi-center study subject moderate-severe OA . Subjects randomize receive flavocoxid 250 mg bid , flavocoxid 500 mg bid , naproxen 500 mg bid placebo 2:2:2:1 ratio . Subjects take study material twice daily twelve ( 12 ) week . After 12 week visit subject placebo arm re-randomized two flavocoxid arm . All subject continue study additional 12 week . Subjects keep diary noting date onset symptom change ( good worse ) , adverse event cost aspect medical care relate directly indirectly osteoarthritis . Laboratory study inflammatory marker draw archive baseline 12 week visit . In addition , subgroup subject arthrocenteses performed baseline 12 week visit synovial fluid archive study intra-articular inflammatory marker .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>OA Knee KL Grade 23 Positive response NSAIDS KL grade 1 0r 4 OA knee History GI Bleed within past 5 year Chronic bleeding disorder</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>